Cargando…
Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma
BACKGROUND: Nasopharyngeal carcinoma (NPC) is one of the most common human head and neck cancers with high incidence in Southern China, Southeast Asia and North Africa. Because of its nonspecific symptoms, the early diagnosis of NPC is very difficult. The 5-year survival rate is not ideal in spite o...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779195/ https://www.ncbi.nlm.nih.gov/pubmed/26949513 http://dx.doi.org/10.1186/s13578-016-0082-x |
_version_ | 1782419592205828096 |
---|---|
author | Guo, Yuanwei Luo, Weihao Hu, Zheng Li, Jia Li, Xiaojie Cao, Huiqiu Li, Jun Wen, Bo Zhang, Jian Cheng, Hao Guo, Wangyuan Tan, Tan Luo, Dixian |
author_facet | Guo, Yuanwei Luo, Weihao Hu, Zheng Li, Jia Li, Xiaojie Cao, Huiqiu Li, Jun Wen, Bo Zhang, Jian Cheng, Hao Guo, Wangyuan Tan, Tan Luo, Dixian |
author_sort | Guo, Yuanwei |
collection | PubMed |
description | BACKGROUND: Nasopharyngeal carcinoma (NPC) is one of the most common human head and neck cancers with high incidence in Southern China, Southeast Asia and North Africa. Because of its nonspecific symptoms, the early diagnosis of NPC is very difficult. The 5-year survival rate is not ideal in spite of great innovations in radiation and chemotherapy treatments. Highly sensitive and specific prognostic biomarkers are eager for NPC clinical diagnosis. To find specific target molecules is very important for individualized treatment. Aldo–keto reductase B10 (AKR1B10) is closely related to tumorigenesis and tumor development, and however, its expression level in NPC tissues is not clear. RESULTS: AKR1B10 expression levels were validated in benign, para-cancerous nasopharyngeal and NPC tissues by immunohistochemical evaluation. AKR1B10 was positively expressed in 42 (82.4 %) of 51 benign specimens, and 235 (98.7 %) of 238 para-carcinoma specimens. This percentage was significantly higher than 44.5 % (133/299) in nasopharyngeal carcinoma tissue (p < 0.01). AKR1B10 mRNA quantitative levels detected by real-time quantitative RT-PCR in 90 NPC tissue samples (0.10 ± 0.21) were significantly lower than that in 15 benign tissue samples (1.03 ± 1.12) (p < 0.01). AKR1B10 expression levels in NPC were correlated negatively with T-classification, lymph node metastasis (p < 0.05). We established nasopharyngeal cancer monoclonal cells CNE-2/AKR1B10 with AKR1B10 stable expression and CNE-2/vector cells without AKR1B10 expression by using a modified lentivirus-mediated method, and found that AKR1B10 inhibited the proliferation of CNE-2/AKR1B10 cells by using MTT assay and flow cytometry, and cell migration by in vitro scratch test. CONCLUSION: Taken together, our data suggest that low expression of AKR1B10 is an independent prognostic indicator in nasopharyngeal carcinoma, and that AKR1B10 may be involved in regulating the proliferation and migration of nasopharyngeal cancer cells. |
format | Online Article Text |
id | pubmed-4779195 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47791952016-03-06 Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma Guo, Yuanwei Luo, Weihao Hu, Zheng Li, Jia Li, Xiaojie Cao, Huiqiu Li, Jun Wen, Bo Zhang, Jian Cheng, Hao Guo, Wangyuan Tan, Tan Luo, Dixian Cell Biosci Research BACKGROUND: Nasopharyngeal carcinoma (NPC) is one of the most common human head and neck cancers with high incidence in Southern China, Southeast Asia and North Africa. Because of its nonspecific symptoms, the early diagnosis of NPC is very difficult. The 5-year survival rate is not ideal in spite of great innovations in radiation and chemotherapy treatments. Highly sensitive and specific prognostic biomarkers are eager for NPC clinical diagnosis. To find specific target molecules is very important for individualized treatment. Aldo–keto reductase B10 (AKR1B10) is closely related to tumorigenesis and tumor development, and however, its expression level in NPC tissues is not clear. RESULTS: AKR1B10 expression levels were validated in benign, para-cancerous nasopharyngeal and NPC tissues by immunohistochemical evaluation. AKR1B10 was positively expressed in 42 (82.4 %) of 51 benign specimens, and 235 (98.7 %) of 238 para-carcinoma specimens. This percentage was significantly higher than 44.5 % (133/299) in nasopharyngeal carcinoma tissue (p < 0.01). AKR1B10 mRNA quantitative levels detected by real-time quantitative RT-PCR in 90 NPC tissue samples (0.10 ± 0.21) were significantly lower than that in 15 benign tissue samples (1.03 ± 1.12) (p < 0.01). AKR1B10 expression levels in NPC were correlated negatively with T-classification, lymph node metastasis (p < 0.05). We established nasopharyngeal cancer monoclonal cells CNE-2/AKR1B10 with AKR1B10 stable expression and CNE-2/vector cells without AKR1B10 expression by using a modified lentivirus-mediated method, and found that AKR1B10 inhibited the proliferation of CNE-2/AKR1B10 cells by using MTT assay and flow cytometry, and cell migration by in vitro scratch test. CONCLUSION: Taken together, our data suggest that low expression of AKR1B10 is an independent prognostic indicator in nasopharyngeal carcinoma, and that AKR1B10 may be involved in regulating the proliferation and migration of nasopharyngeal cancer cells. BioMed Central 2016-03-05 /pmc/articles/PMC4779195/ /pubmed/26949513 http://dx.doi.org/10.1186/s13578-016-0082-x Text en © Guo et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Guo, Yuanwei Luo, Weihao Hu, Zheng Li, Jia Li, Xiaojie Cao, Huiqiu Li, Jun Wen, Bo Zhang, Jian Cheng, Hao Guo, Wangyuan Tan, Tan Luo, Dixian Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma |
title | Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma |
title_full | Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma |
title_fullStr | Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma |
title_full_unstemmed | Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma |
title_short | Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma |
title_sort | low expression of aldo–keto reductase 1b10 is a novel independent prognostic indicator for nasopharyngeal carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779195/ https://www.ncbi.nlm.nih.gov/pubmed/26949513 http://dx.doi.org/10.1186/s13578-016-0082-x |
work_keys_str_mv | AT guoyuanwei lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma AT luoweihao lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma AT huzheng lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma AT lijia lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma AT lixiaojie lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma AT caohuiqiu lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma AT lijun lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma AT wenbo lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma AT zhangjian lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma AT chenghao lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma AT guowangyuan lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma AT tantan lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma AT luodixian lowexpressionofaldoketoreductase1b10isanovelindependentprognosticindicatorfornasopharyngealcarcinoma |